OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer

Jonathan Tammela, Akiko Uenaka, Toshiro Ono, Yuji Noguchi, Achim A. Jungbluth, Paulette Mhawech-Fauceglia, Feng Qian, Sally Schneider, Sameer Sharma, Deborah Driscoll, Shashikant Lele, Lloyd J. Old, Eiichi Nakayama, Kunle Odunsi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.

Original languageEnglish
Pages (from-to)903-910
Number of pages8
JournalInternational Journal of Oncology
Volume29
Issue number4
Publication statusPublished - Oct 2006

Fingerprint

Serum
Humoral Immunity
Antigens
Immunohistochemistry
Ovarian epithelial cancer
TES
Active Immunotherapy
Testicular Neoplasms
Neoplasm Antigens
Reverse Transcriptase Polymerase Chain Reaction
Immunotherapy
Thymus Gland
Histology
Leukocytes
Enzyme-Linked Immunosorbent Assay
Cell Line
Polymerase Chain Reaction
Survival
Antibodies
Population

Keywords

  • Antibody
  • Immunogenicity
  • Immunohistochemistry
  • Ovarian tumor antigen
  • Prognostic indicator

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tammela, J., Uenaka, A., Ono, T., Noguchi, Y., Jungbluth, A. A., Mhawech-Fauceglia, P., ... Odunsi, K. (2006). OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. International Journal of Oncology, 29(4), 903-910.

OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. / Tammela, Jonathan; Uenaka, Akiko; Ono, Toshiro; Noguchi, Yuji; Jungbluth, Achim A.; Mhawech-Fauceglia, Paulette; Qian, Feng; Schneider, Sally; Sharma, Sameer; Driscoll, Deborah; Lele, Shashikant; Old, Lloyd J.; Nakayama, Eiichi; Odunsi, Kunle.

In: International Journal of Oncology, Vol. 29, No. 4, 10.2006, p. 903-910.

Research output: Contribution to journalArticle

Tammela, J, Uenaka, A, Ono, T, Noguchi, Y, Jungbluth, AA, Mhawech-Fauceglia, P, Qian, F, Schneider, S, Sharma, S, Driscoll, D, Lele, S, Old, LJ, Nakayama, E & Odunsi, K 2006, 'OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer', International Journal of Oncology, vol. 29, no. 4, pp. 903-910.
Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. International Journal of Oncology. 2006 Oct;29(4):903-910.
Tammela, Jonathan ; Uenaka, Akiko ; Ono, Toshiro ; Noguchi, Yuji ; Jungbluth, Achim A. ; Mhawech-Fauceglia, Paulette ; Qian, Feng ; Schneider, Sally ; Sharma, Sameer ; Driscoll, Deborah ; Lele, Shashikant ; Old, Lloyd J. ; Nakayama, Eiichi ; Odunsi, Kunle. / OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. In: International Journal of Oncology. 2006 ; Vol. 29, No. 4. pp. 903-910.
@article{c529c4ee9e7245eb801d3b83fc7e70ff,
title = "OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer",
abstract = "OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69{\%}) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10{\%}) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69{\%} of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.",
keywords = "Antibody, Immunogenicity, Immunohistochemistry, Ovarian tumor antigen, Prognostic indicator",
author = "Jonathan Tammela and Akiko Uenaka and Toshiro Ono and Yuji Noguchi and Jungbluth, {Achim A.} and Paulette Mhawech-Fauceglia and Feng Qian and Sally Schneider and Sameer Sharma and Deborah Driscoll and Shashikant Lele and Old, {Lloyd J.} and Eiichi Nakayama and Kunle Odunsi",
year = "2006",
month = "10",
language = "English",
volume = "29",
pages = "903--910",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer

AU - Tammela, Jonathan

AU - Uenaka, Akiko

AU - Ono, Toshiro

AU - Noguchi, Yuji

AU - Jungbluth, Achim A.

AU - Mhawech-Fauceglia, Paulette

AU - Qian, Feng

AU - Schneider, Sally

AU - Sharma, Sameer

AU - Driscoll, Deborah

AU - Lele, Shashikant

AU - Old, Lloyd J.

AU - Nakayama, Eiichi

AU - Odunsi, Kunle

PY - 2006/10

Y1 - 2006/10

N2 - OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.

AB - OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.

KW - Antibody

KW - Immunogenicity

KW - Immunohistochemistry

KW - Ovarian tumor antigen

KW - Prognostic indicator

UR - http://www.scopus.com/inward/record.url?scp=38949172355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949172355&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 903

EP - 910

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -